Unveiling the threat: Characterization of *Clostridioides difficile* Infection in the Northwest Region of Buenos Aires between 2019-2023 and Associated Risk Factors redefined through a Meta-Analysis

Angela María Barbero[1,2,#], Nicolás Diego Moriconi[1,#], Sabina Palma[1,2,#], Josefina Celano[1], María Gracia Balbi[3], Lorenzo Sebastián Morro[1], María Martina Calvo Zarlenga[4], Jorgelina Suárez[3,5], María Guadalupe Martínez[3], Mónica Graciela Machain[3], Carlos Gabriel Altamiranda[4], Gabriel Erbiti[4,5], Rodrigo Emanuel Hernández Del Pino[1,2, ζ], Virginia Pasquinelli[1,2, *, ζ].

1 Centro de Investigaciones Básicas y Aplicadas (CIBA), Universidad Nacional del Noroeste de la Provincia de Buenos Aires (UNNOBA). B6000DNE, Buenos Aires, Argentina.

2 Centro de Investigaciones y Transferencias del Noroeste de la Provincia de Buenos Aires (CIT NOBA), UNNOBA-Universidad Nacional de San Antonio de Areco (UNSAdA)-Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Buenos Aires, Argentina.

3 Servicio de Laboratorio, Sala de Microbiología, Hospital Interzonal General de Agudos (HIGA) Dr. Abraham F. Piñeyro, Junín, Buenos Aires, Argentina

4 Clínica Centro Médico Privado SRL, Junín, Buenos Aires, Argentina

5 Universidad Nacional del Noroeste de la Provincia de Buenos Aires (UNNOBA). B6000DNE, Buenos Aires, Argentina.

[#] Angela María Barbero, Nicolás Diego Moriconi and Sabina Palma share first authorship.

[ζ] Rodrigo Emanuel Hernández Del Pino Rodrigo and Virginia Pasquinelli share the last authorship.

*Corresponding author: virpasquinelli@gmail.com, Tel: +5492364582417, Address: Coronel Borges 379, Junín (Postal Code 6000), Buenos Aires, Argentina.

Conflict of interest. *The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.*

1 in 5 diarrheas is caused by *C. difficile* in the Northwest region of Buenos Aires, Argentina. One third of the cases were community-acquired and involved toxigenic strains. Comparison through meta-analysis identified known and also new risk factors.

Abstract

Clostridioides difficile stands as the leading cause of hospital acquired enteric infection in developed countries. In Argentina, the epidemiology of *Clostridioides difficile* infection (CDI) is currently poorly characterized. Therefore, we conducted a retrospective case-control study evaluating the prevalence of CDI in 249 stool samples collected between 2019 and 2023 in the Northwest region of Buenos Aires. The presence of *C. difficile* was detected by combining three techniques (EIA, PCR and toxigenic culture) in a diagnostic algorithm. Clinical and demographic data from patients was also analyzed to identify CDI-associated risk factors. 1 in 5 patients presented *C. difficile* as the etiological agent of diarrhea and the 80% of CDI+ cases carried toxigenic strains, with a third of cases acquired in the community. Age ≥69 years, previous use of antibiotics, previous hospitalization and previous episodes of CDI emerged as predisposing factors for CDI in our study cohort. Blood parameters such as an elevated number of leukocytes and platelets, a decreased basophil count, and an increased urea concentration were identified as indicators of CDI. We also carried out a systematic review and a meta-analysis where we contrasted our results with 39 studies selected from different countries around the world. At the global level, the meta-analysis highlighted advanced age, previous consumption of antibiotics and previous hospitalization as CDI risk factors and the leukocyte count as an indicator of CDI. These results emphasize the importance of epidemiological studies and reveal crucial information for healthcare decision-making regarding CDI.

Keywords: *C. difficile*, epidemiology, risk factors, meta-analysis

Running title: Risk factors and meta-analysis of CDI


STUDY COHORT
Diagnostic algorithm
Clinical records
20%
of patients had C. difficile as the causal agent of their diarrheas
30%
of CDI infections occurred in the community setting
80%
of the patients were infected with toxigenic strains
100%
of infected patients had a moderate diarrhea classification
RISK FACTORS
Advanced age
Prior antibiotic use
Prior hospitalization
Prior CDI
Leukocytosis
Thrombocytosis
Basophilopenia
Elevated urea
Meta-analysis
GLOBAL RISK FACTORS
Advanced age
Female
Prior antibiotic use
Prior hospitalization
Leukocytosis
Chronic kidney disease
Heart diseases

58

Introduction

Clostridioides difficile infection (CDI) is considered as the most frequent hospital-acquired disease [1,2]. Since 2019, the Centers for Disease Control (CDC) have identified *C. difficile* as an "urgent threat", with the immediate need to implement prevention and control actions [3]. *C. difficile* is a Gram positive, anaerobic and spore-forming bacterium that causes intestinal damage primarily through the production of two main toxins: toxin A (TcdA) and toxin B (TcdB) [4]. These toxins play a crucial role in the pathogenesis of CDI by damaging the cells lining the gut. CDI can be life-threatening, ranging from mild diarrhea to pseudomembranous colitis and causing nearly 500,000 cases per year in the United States [5].

CDI is also a major economic burden to the health care systems, which is closely linked to the high recurrence rates of this infection. Although standard treatments resolve CDI in most cases, up to 35% of CDI-treated patients will experiment a recurrence of the disease with aggravated symptoms [5]. Common therapy for CDI includes antibiotics such as metronidazole for mild cases and vancomycin or fidaxomicin for moderate to severe cases [6]. Therapies with the human antibody bezlotoxumab against *C. difficile* toxin B or Fecal Microbiota Transplant (FMT) to restore the balance of the microbiome have been recommended to treat or prevent recurrences [7,8].

Regarding global epidemiology, while healthcare-associated CDI has declined in recent years, the incidence of community-acquired CDI is on the rise [9–14]. The main transmission route for *C. difficile* is through direct Person-to-Person contact by the fecal-oral route [15]. *C. difficile* spores constitute the main form of resistance and can persist in the environment for long periods [16,17]. Then, contaminated surfaces, food or water, as well as asymptomatic carriers, are typical sources of community transmission [18–20].

Several risk factors are associated with the development of CDI. The use of antimicrobials with emphasis on broad-spectrum antibiotics, has been described as the most significant risk factor for CDI [21,22]. These antibiotics can disrupt the normal balance of bacteria in the gastrointestinal tract, generating dysbiosis and so allowing *C. difficile* overgrow in the gut. Hospitalization in healthcare facilities and advanced age, which can be related to weakened immune systems and a higher likelihood of residing in healthcare settings, also constitute important risk factors [22]. The use of stomach acid regulators, such as proton pump inhibitors (PPIs) and H2 blockers, has been associated with an increased risk of CDI [23]; however, this is still under debate. Previous episodes of CDI increase the risk of recurrence [24]. Finally, several underlying health conditions that could compromise the immune system could contribute to increased susceptibility or severity of the infection. Comorbidities such as Inflammatory Bowel Disease (IBD) [25], Crohn's disease [25], ulcerative colitis [25], diabetes [26] and chronic kidney disease (CKD) [27] can enhance the risk of CDI.

Certain clinical procedures (e.g. chemotherapy treatments and gastrointestinal surgery), malnutrition or enteral nutrition, organ transplantation along with immunosuppressive medications and blood disorders may also elevate the risk of CDI [28,29].

Understanding geographical variations in prevalence by studying CDI epidemiology and risk factors is essential for preventing, controlling, and managing the infection. In Latin America, and particularly in Argentina, comprehensive epidemiological data on CDI are limited. It has been reported that patients with diarrhea are not routinely tested for *C. difficile* in developing countries and, when tested, very often only the enzyme immunoassay (EIA) is used [30–32]. This could lead to an underestimation in the diagnosis and high economic burdens for the health system. Our retrospective study (2019-2023) assesses the prevalence of *C. difficile* among health care centers of the Northwest region of Buenos Aires, Argentina. Furthermore, with the aim to characterize our study cohort, we analyzed the demographic and clinical data of the patients and we conducted a meta-analysis to compare our findings with global reports.

Methodology

Human Samples and Participating Institutions

The research was carried out in accordance with the Declaration of Helsinki (2013) and approved by the UNNOBA (Universidad Nacional del Noroeste de la Provincia de Buenos Aires) Ethics Committee (COENOBA).

Fecal samples from hospitalized adult patients with diarrhea were collected after obtaining informed consents and frozen at -20 °C until use. The samples were derived from the following health-care centers: Hospital Interzonal General de Agudos (HIGA) Abraham Félix Piñeyro, Clínica Centro Médico Privada SRL and Clínica IMEC. Samples received between January 1, 2019 and December 31, 2023 from Sanitary Region III of Buenos Aires, Argentina **(Supplementary Fig. 1)** were included in this analysis.

Patients characterization

The presence of *C. difficile* was determined in the fecal samples using a diagnostic algorithm **(Supplementary Fig. 2)** as recommended by Crobach et al. in 2016 [33]. Briefly, three tests were used in a retrospective approach: Enzyme immunoassay (EIA, CoproStripTM *C. difficile* GDH + Toxin A + Toxin B (Savyon® Diagnostics Ltd)), Polymerase Chain Reaction from stool samples (PCR, Taq Phire Tissue Direct PCR Master Mix (Thermo Fisher)) and Toxigenic culture (stool culture in CHROMAgar™ *C. difficile* plates + PCR from isolated *C difficile* colonies).

Patients were defined as CDI+ or CDI- and clinical, demographic and blood parameters were evaluated **(Table 1)**.

CDI classifications by setting of acquisition and severity were defined according to the Infectious Diseases Society of America (IDSA) criteria [34].

Clinical-demographical parameters	Blood parameters
Age	Leukocytes (cells/mm^3)
Biological Sex	Neutrophils (cells/mm^3)
Previous hospitalization	Monocytes (cells/mm^3)
Previous consumption of Antibiotics	Lymphocytes (cells/mm^3)
Antibiotics use during hospitalization	Eosinophils (cells/mm^3)
Presence of comorbidities	Basophils (cells/mm^3)

Previous consumption of Proton Pump Inhibitors	Platelets (cells/mm^3)
Previous CDI	Urea (mg/dl)
Place of hospitalization	Creatinine (mg/dl)
Need for Intensive Care Unit (ICU)	Albumin (g/dl)
Origin	
Diarrhea classification	
Shock	
Death	

Table 1. Clinical, demographic and blood parameters evaluated in CDI+ and CDI- patients.

Meta-analysis design

A bibliographic search was carried out using PubMed and Google Scholar databases in addition to the AI SciSpace tool. The reports that fulfilled the definition criteria of cases and controls were selected. The meta-analysis workflow is summarized in **Fig. 4**.

Statistical Analysis

For clinical, demographic and blood parameters comparisons, parametric t-test or non-parametric Mann-Whitney test for unpaired samples were used. Fisher's exact test was used to analyze the frequency distribution of qualitative/nominal variables. Data was analyzed using GraphPad Prism 8.0.1 software (San Diego, CA, USA) and p values <0.05 were considered statistically significant.

For the meta-analysis, the “Metafor” package from RStudio (2023.06.1+524 version) was used [35]. The Odds Ratio (OR, for categorical variables) and the Standardized Mean Difference (SMD, for continuous variables) were calculated and a REML (Random Effect Maximum Likelihood) model was employed. Models with a p value <0.05 were considered as potential predictors of CDI incidence risk.

Results and Discussion

CDI prevalence in Northwest Buenos Aires

In Argentina, studies and reports on CDI are scarce and heterogeneous [36–39]. In order to contribute to a better understanding of the disease, we conducted a retrospective analysis of 249 fecal samples received between 2019-2023 from Sanitary Region III of Buenos Aires.

We determined *C. difficile* as the causal agent of one in five diarrheas (21.29%) **(Fig. 1 a)** and we detected that more than the 80% of the patients were infected with toxigenic strains; indicated by the presence of *C. difficile* Toxin B in the stool samples **(Fig. 1 b)**. This percentage was similar to the worldwide reported prevalence, where CDI is the underlying cause of 15 to 20% of diarrhea associated with the use of antibiotics [40].

When analyzing the cases on an annual basis, the frequency of CDI ranged around 20% from 2019 to 2023 **(Fig. 1 c)**. Interestingly, the highest incidence in our study cohort was observed during 2020, duplicating the percentage of CDI+ cases compared to the rest of the years **(Fig. 1 c)**. In relation to this, the COVID-19 pandemic brought about the preventive use of broad-spectrum antibiotics to avoid bacterial coinfections; which could be associated with the increase in detection [41–44]. Nevertheless, CDI detection could have been impacted by the decrease in the number of tests, a fact that was corroborated in multiple studies carried out during the early stages of the pandemic [45–47]. Additionally, there could also be an underestimation of CDI cases [48,49] since SARS-CoV-2 frequently causes gastrointestinal symptoms similar to those of C*. difficile* [50].

Regarding the severity of the diarrhea, all infected patients had a moderate classification **(Fig. 1 d)**. Importantly, the majority of CDI infections occurred in the community setting (56.41%) (**Fig. 1 e**). 33.33% of the patients presented with community-acquired CDI, 23.08% with community-acquired CDI associated with healthcare environments, and the remaining 43.59% of the patients were hospital-acquired (**Fig. 1 e**). This is particularly notable, since the epidemiology of CDI has changed in the last two decades. The 027 strain, responsible for clinical outbreaks in the early 2000s [51], has recently decreased its incidence in part due fluoroquinolones restriction, prevention measures and to improvements in detection tests that have allowed a better characterization of the circulating ribotypes [52–56]. Additionally, an increase in strains associated with community infection (e.g. 078, 014 in Europe and 106 in the US) has been reported in recent years, with community-acquired cases rising above 40% [11,57–59].



Figure 1. CDI prevalence in Northwestern Buenos Aires.

249 stool samples were evaluated using the diagnostic algorithm. a) Donut graph showing positive, negative and discordant results for the presence of *C. difficile*. b) Donut graph showing the percentage of toxigenic strains (presence of Toxin B) detected in the stool samples. c) CDI+ and CDI- results classified on an annual basis from 2019 to 2023. d) CDI classification. e) CDI classification by setting of acquisition.

Risk factors

After classifying the patients as CDI+ or CDI-, we determined the risk factors that could be involved in the prevalence of CDI.

As seen in **Fig. 2 a**, we found significant differences in the age of CDI+ and CDI- populations, with the CDI+ patients presenting a higher average age (CDI+: mean = 72 years vs. CDI-: mean = 65 years). By using a ROC curve analysis, we established a cut-off point of 69 years for advanced age as a risk factor in our cohort **(Fig. 2 b)**. Elderly patients have a greater probability of receiving broad-spectrum antibiotics, being hospitalized or staying longer in hospital settings partly due to the presence of comorbidities [60,61].

With age, the immune system decreases its functions and also older individuals develop inflammageing, which could impact in the resolution of the infection; a fact that was observed for neutrophils [62] and serum IgG against *C. difficile* toxins [63–65].

Regarding biological sex, no differences were found for the proportion of males and females between both patient populations **(Fig. 2 c)**.

Consumption of antibiotics in the 3 months prior to the diagnosis of CDI, as well as previous hospitalizations and infections with *C. difficile*, could be considered risk factors that predisposes to CDI in our study cohort **(Fig. 2 d, e and f)**. Hospitals and healthcare facilities are common environments for *C. difficile* transmission since they can be easily colonized by spores that persist on surfaces for months [66,67]. Previous consumption of antibiotics is directly related to the dysbiosis of the microbiota that enables the colonization of *C. difficile* and is typically consider as the main risk factor for CDI [68,69]. Some antibiotics, such as clindamycin, broad-spectrum penicillins, cephalosporins and fluoroquinolones alter the microbiota to a greater extent than others [68,70,71]. When analyzing the families of antibiotics consumed by CDI+ patients, we observed that 56.52% had taken some kind of penicillin prior to diagnosis **(Fig. 2 g)**.

On the other hand, the consumption of proton pump inhibitors (PPI) prior to diagnosis and the presence of comorbidities did not show significant differences between CDI- and CDI+ patients **(Fig. 2 h and i)**. **Fig. 2 j** shows a breakdown of the comorbidities reported in the patients under study. Although they were analyzed individually, no substantial variations were found between the CDI+ and CDI- population for any of them.

No differences were found regarding the variables referring to the evolution of patients during admission to health centers such as *hospitalization in common floor or ICU, need for ICU, shock and death* **(Supplementary Fig. 3)**.



Figure 2. CDI associated risk factors.

Evaluation of risk factors associated with CDI. a) Age (years), b) ROC curve to establish the age cut-off point, c) biological sex, d) prior antibiotics (ATB) consumption, e) prior hospitalization, f) prior CDI, g) antibiotic breakdown by family, h) prior PPI consumption, i) comorbidities, j) breakdown of specific comorbidities (the white number inside the bars represents the number of patients with the comorbidity).

a) Mann-Whitney test. c, d, e, f, h, and i) Fisher's exact test. Stacked bars represent the percentage of patients for each parameter. ns= non-significant; *, p

Blood and serum parameters

We also analyzed the patients' blood counts and serum parameters that were measured on the day of fecal sample collection.

We observed a significant increase in the number of leukocytes **(Fig. 3 a)** and platelets **(Fig. 3 j)** in patients infected with *C. difficile*. When analyzing the count of lymphocytes, monocytes and neutrophils individually between both patient populations, although an increase was evident, we did not find significant differences **(Fig. 3 b, c and d)**. However, it is important to note that CDI+ patients had increased at least two of these leukocyte populations compared to CDI- patients at the time of diagnosis **(Fig. 3 e, f and g)**. Although some studies have highlighted that an elevated white blood cell (WBC) count is frequently observed in the context of CDI [72 73 74], little has been explored in using elevated WBC count as a predictor of this infection. In this regard, we agree with Vargas et al. [75] in that the total leukocyte count alone is not a specific indicator for CDI. Previous work evaluating platelet count in CDI episodes reported controversial results, assigning them both a beneficial and detrimental role in relation to clinical symptoms [76–85]. We have recently shown that platelets bind to *C. difficile* and promote its uptake by human macrophages using macropinocytic pathways [86]. Therefore, we consider that platelets in CDI could be fundamental for the resolution of the infection and that further studies are needed to unravel their role during CDI.

Regarding the rest of the blood parameters evaluated, while a significant decrease in basophils count was observed **(Fig. 3 h)**, the eosinophil count was not affected by the presence of *C. difficile* **(Fig. 3 i)**. To the best of our knowledge, to date there are no reports on the role of basophils in CDI. Nevertheless, the potential role of CCL-5, a basophilic recruiter chemokine, has been highlighted in CDI [87,88]

No differences were evident for creatinine and albumin levels **(Fig. 3 j and k)**, but an elevated urea concentration stood out in patients infected with *C. difficile* **(Fig. 3 m)**. Moreover, the BUN (Blood Urea Nitrogen)/Creatinine ratio was significantly elevated in CDI patients **(Fig. 3 n)**. Elevated BUN ratios have been associated with complications of CDI [89] as well as with higher mortality rates [90] and high urea levels were also proposed as a risk factor for severe CDI [91].


a)
Leukocytes (cel./mm3)
*
CDI-
CDI+
b)
Lymphocytes (cel./mm3)
ns (p = 0.0505)
c)
Monocytes (cel./mm3)
ns (p = 0.0625)
d)
Neutrophils (cel./mm3)
ns (p = 0.0714)
e)
Limphocytes+Monocytes (cel./mm3)
f)
Limphocytes+Neutrophils (cel./mm3)
g)
Neutrophils+Monocytes (cel./mm3)
h)
Basophils (cel./mm3)
**
i)
Eosinophils (cel./mm3)
ns
j)
Platelets (cel./mm3)
k)
Creatinine (mg/dl)
l)
Albumin (g/dl)
m)
Urea (mg/dl)
n)
Ratio BUN / Creatinine

288

Figure 3. Blood and serum parameters in CDI+ and CDI- patients.

Number of a) Leukocytes (cells/mm^3), b) lymphocytes (cells/mm^3), c) monocytes (cells/mm^3), d) neutrophils (cells/mm^3), e) lymphocytes plus monocytes (cells/mm^3), f) lymphocytes plus neutrophils (cells/mm^3), g) neutrophils plus monocytes (cells/mm^3), h) basophils (cells/mm^3), i) eosinophils (cells/mm^3) and j) platelets (cells/mm^3). Levels of k) creatinine (mg/dl), l) albumin (g/dl) and m) urea (mg/dl). n) BUN (blood urea nitrogen)/creatinine ratio.

a-i and k-n) Mann-Whitney test. j) unpaired t test. Violin plots show the distribution of the data. ns= non-significant; *, $p<0.05$; **, $p<0.01$.

Meta-analysis

We finally performed a meta-analysis to obtain more robust and reliable conclusions about the CDI associated parameters evaluated in our cohort. We defined the selection criteria (**Fig. 4 a**) and carried out a systematic review that allowed us to select 40 independent case/control type studies (**Table 2**) from the countries shown in light grey in **Fig. 4 b**.



Figure 4. Flow chart of the studies and countries screened and included in the Meta-analysis.

a) The obtained results regarding clinical and demographic characteristics of the CDI+ and CDI- patients in our cohort were contrasted against findings of other studies through a meta-analysis by RStudio package “Metafor”. After initial identification, eligibility criteria were applied and 39 reports were included in the meta-analysis along with our data. CDI- patients were considered as the control group.

b) World map showing the countries from which the studies included in the meta-analysis come (light gray). The circles contain the number of studies selected per country.

Countries	Studies
Argentina	Lopardo, G. et al, 2015 [39] **OUR study**
Brazil	Lopes Cançado, G. G. et al, 2018 [92]
Canada	Lowe, D. O. et al, 2006 [93]
China	Dai, W. et al, 2020 [94] Li, Y. et al, 2016 [95] Lv, Z. et al, 2014 [96] Tang, C. et al, 2018 [97] Zhou, F, F, et al, 2014 [98]
Colombia	Carvajal, C. et al, 2017 [99] Salazar, C, L. et al, 2017 [100]
Denmark	Soes, L. M. et al, 2014 [101]
France	Le Monnier, A. et al, 2022 [102]
Hungary	Kurti, Z. et al, 2015 [103]
Iceland	Vesteinsdottir, I. et al, 2012 [104]
India	Ingle, M. et al, 2011 [105] Ingle, M. et al, 2013 [106]
Japan	Mori, N. et al, 2015 [107]
Mexico	Morfin-Otero, R. et al, 2016 [108]
Poland	Czepiel, J. et al, 2014 [109]
South Africa	Legenza, L. et al, 2018 [110] Rajabally, N. et al, 2013 [111]
South Korea	Han, S. H. et al, 2014 [112]
Taiwan	Lee, Y. C. et al, 2012 [113]; Lin C. Y. et al, 2022 [114]
Thailand	Thipmontree, W. et al, 2011 [115]
Turkey	Ergen, E. K. et al, 2009 [116]
United Kingdom	Dial, S. et al, 2005 [117] Dial, S. et al, 2008 [118] Marwick, C. A. et al, 2013 [119] Suissa, D. et al, 2012 [120] Wilcox, M. H. et al, 2008 [121]
United States	Baxter, R. et al, 2008 [122] Haddad, F. G. et al, 2019 [123] Kuntz, J. L. et al, 2011 [124] Kutty, P. K. et al, 2010 [125] Kwon, S. et al, 2017 [126] Naggie, S. et al, 2011 [127] Tabak, P. Y. et al, 2015 [128] Tartof, S. Y. et al, 2015 [129]

Table 2. Countries and studies included in the meta-analysis.

The effects for each of the variables evaluated in the meta-analysis are summarized in **Table 3**.

RISK PREDICTOR	OR
Age	1,19 **
Biological sex	0,89 *
Prior ATB consumption	3,02 ***
Prior PPI consumption	1,29 ns
Prior hospitalization	2,45 ***
Prior CDI	1,76 ns
WBC (10^9 cel/mm^3)	1,35 *
Platelets (10^9 cel/ mm^3)	1,54 ns
Comorbidities	
Diabetes *mellitus*	1,26 ns
Heart disease	1,41 *
Kidney disease	2,23 ***
HIV	1,00 ns

Table 3. Summary of risk predictors from the meta-analysis.

The dataset included 11,596 individuals with CDI and 536,467 matched controls **(Table 4)**. Overall, the distribution of biological sex was 40.06% male vs. 59.94% female, being 44.33% vs. 55.67% in the CDI+ population and 39.98% vs. 60.02% in the control group. The demographic parameters Age (OR= 1.19; 95% CI, 1.06 to 1.35) and Biological Sex (OR= 0.89; 95% CI, 0.81 to 0.99) obtained significant models, which implies that, globally, advanced age and female biological sex are associated with a higher risk of CDI **(Fig. 5 a and b).**

9.11% of the included individuals were previously exposed to antibiotics and 22.18% to PPI. Both antibiotic (CDI+ 39.95% vs. CDI- 8.52%) and PPI (CDI+ 29.87% vs. CDI- 21.76%) consumption was higher among those patients infected with *C. difficile* **(Table 4)**. In this analysis, which ignored antibiotic subclasses, we found that the pooled impact of any antibiotic exposure (OR= 3.02; 95% CI, 2.32 to 3.94) increased the risk of CDI by a multiple of 3 **(Fig. 5 c)**. A longer duration of antibiotic therapy, as well as a greater number of antibiotics administered increase the probability of CDI [70]. The risk of acquiring CDI could be 8 to 10 times higher during antibiotic therapy, even three months after its completion, with the first month being the one with the highest risk [130].

Regarding PPIs as risk factors for CDI, there is an arduous discussion with some reports showing around 40-71.4% of hospitalized patients received PPI therapy during hospitalization [131–133] and others supporting the idea that PPIs could trigger long-term adverse effects trough changes on the microbiota composition [134,135]. In our meta-analysis, there was no evidence of the impact of PPI on CDI risk **(Fig. 5 d)**.

Previous hospitalization emerged as the second most influential predictor for CDI risk (OR= 2.46; 95% CI, 1.90 to 3.17) **(Fig. 5 e)**. Among the CDI+ patients included in the meta-analyses, 27.88% had been hospitalized prior to diagnosis **(Table 4)** while only 16.80% in the control group.

Previous episodes of CDI are widely reported as a risk factor for subsequent cases and/or recurrences in patients. However, in this meta-analysis previous CDI was not a predictor of risk **(Fig. 5 f)** which could be attributed to the fact that only 4 of the 40 included studies provided this type of data [56,103,120,123]. Actually, when evaluating the Forest Plot for this variable in detail, the studies show the same trend as our epidemiological study when considering previous CDI as a risk factor.

When evaluating comorbidities, both heart diseases (OR= 1.41; 95% CI, 1.02 to 1.94) and chronic kidney disease (OR= 2.23; 95% CI, 1.38 to 3.61) exhibited models with significant effects **(Fig. 5 g and h)**, indicating that these pathologies increase the risk of CDI. The rest of the tested comorbidities were not associated with a higher risk of infection **(Fig. 5 i and j)**. The presence of comorbidities has been widely reported as a condition that facilitates colonization and infection by *C. difficile* [136]. A previous meta-analysis found IBD, diabetes, leukemia or lymphoma, kidney failure and solid cancer as the CDI risk-related comorbidities [137].

Finally, blood parameters were analyzed. Increased leukocytes count was also a potential predictor of CDI according to our comparative analysis (OR= 1.36; 95% CI, 1.05 to 1.75) **(Fig. 5 k)**. Although the number of platelets did not show a statistically significant effect **(Fig. 5 l)**, it is important to note that only 2 studies apart from ours evaluated this parameter.

		CDI+	CDI-	TOTAL
Nº of individuals		11596	536467	548467
Sex	Male	44.33%	39.98%	40.06%
	Female	55.67%	60.02%	59.94%
Prior ATB consumption	With	39.95%	8.52%	9.11%
	Without	60.05%	91.48%	90.89%
Prior PPI consumption	With	29.87%	21.76%	22.18%
	Without	70.13%	78.24%	77.82%
Prior hospitalization	With	27.88%	16.80%	17.07%
	Without	72.12%	83.20%	82.93%

Table 4. Meta-analysis dataset.



Figure 5 Forest plots of risk predictors.

Forest plots representative of each variable evaluated in the meta-analysis. a) Age, b) biological sex, c) previous ATB consumption, d) previous PPI consumption, e) prior hospitalization, f) prior CDI, g) heart disease, h) chronic kidney disease, i) diabetes *mellitus*, j) HIV, k) white blood cells (WBC) count (cells/mm^3), l) platelets count (cells/mm^3).

A REML (Random Effect Maximum Likelihood, gray diamond) random effects model was applied. Models with $p<0.05$ (OR/SMD ± CI values less or greater than 1) were considered as potential risk predictors for CDI. Black diamonds represent the means of each of the variables in each study. Bars indicate the lower and upper confidence extremes. Our study (white diamond) is mentioned as *OUR STUDY.*

OR= odds ratio. SMD= standard media deviation. CI= confidence interval

Conclusions

We have defined risk factors associated with CDI and detected modulations in different blood parameters in our study cohort in Argentina. We have also explored the relevance of our findings at a global level by a systematic review and meta-analysis. Our results emphasize the need to detect *C. difficile* as a causal agent of infectious diarrhea in a country where testing is not standardized or routinely performed in the health institutions. Our report provides valuable insights that could contribute to a more efficient surveillance of CDI, diagnosis and follow-up of patients.

Author contributions

Conceptualization: all authors

Formal analysis: AMB, NDM, JC, SP, LSM and REHDP.

Funding acquisition: AMB, SP, REHDP and VP.

Investigation: AMB, NDM, SP, REHDP and VP.

Methodology: all authors.

Software: NDM and REHDP.

Supervision: REHDP and VP.

Writing: AMB wrote the original draft. All authors contributed to the review & editing of this manuscript.

Role of the funding source

This work was supported by Universidad Nacional del Noroeste de la Provincia de Buenos Aires [grant numbers SIB 0618/2019, SIB 2113/2022 and "Proyectos de Investigación Interdisciplinarios de la UNNOBA" Res. CS 2190/2022, to VP]. Agencia Nacional de Promoción Científica y Tecnológica, Fondo para la Investigación Científica y Tecnológica [ANPCyT-FONCyT, grant numbers PICT A 2017-1896 and PICT-2021-I-A-01119 to VP; PICT 2018-03084 IB to RHDP, PICT-2021-I-INVI-00584 to AB and PICT-2021-I-INVI-00208 to SP]. UNNOBA FONCyT [grant number PICTO 2019-00007 to RHDP and VP]. Consejo Nacional de Investigaciones Científicas y Técnicas [CONICET, grant number PIP 2021 11220200103137CO to VP and RHDP].

Acknowledgements

We thank all the patients who voluntarily participated of this study. We also thank Natalia Menite, Lucia Romano and Gastón Villafañe for their technical assistance. We acknowledge the laboratory personnel, medical staff and biochemists who have collaborated in the collection of samples and data during the study period of this report. Finally, we thank Flaticon for the icons used in the graphical abstract of this work.

References

1. Brazier JS. . 1998;47–57.
2. Zhang S, Palazuelos-Munoz S, Balsells EM, et al. . *BMC Infect Dis*;16 . Epub ahead of print 2016. DOI: 10.1186/s12879-016-1786-6.
3. Center for Disease Control and Prevention. . *CDC*;10 . Epub ahead of print 2019. DOI: 10.1186/s13756-020-00872-w.
4. Smits WK, Lyras D, Lacy DB, et al. . DOI: 10.1038/nrdp.2016.20.
5. Feuerstadt P, Theriault N, Tillotson G. . *BMC Infect Dis*. 2023;23:1–8.
6. Di X, Bai N, Zhang X, et al. . *Brazilian J Infect Dis*. 2015;19:339–349.
7. Bainum TB, Reveles KR, Hall RG, et al. . *Microorganisms*. 2023;11:1–22.
8. Phanchana M, Harnvoravongchai P, Wongkuna S, et al. . *World J Gastroenterol*. 2021;27:7210–7232.
9. Burke KE, Lamont JT. . *Gut Liver*. 2014;8:1–6.
10. Freeman J, Bauer MP, Baines SD, et al. . *Clinical Microbiology Reviews*. 2010;23:529–549.
11. Goorhuis A, Bakker D, Corver J, et al. . *Clin Infect Dis*. 2008;47:1162–1170.
12. Chitnis AS, Holzbauer SM, Belflower RM, et al. . *JAMA Intern Med*. 2013;173:1359–1367.
13. Ruiter-Ligeti J, Vincent S, Czuzoj-Shulman N, et al. . *Obstet Gynecol*. 2018;131:387–391.
14. Gupta A, Khanna S. . *Infect Drug Resist*. 2014;7:63–72.
15. Alice Y. Guh, MD, MPH and Preeta K. Kutty, MD M. . *Physiol Behav*. 2019;169:248–256.
16. Lawler AJ, Lambert PA, Worthington T. . *Trends Microbiol*. 2020;28:744–752.
17. Paredes-Sabja D, Shen A, Sorg JA. . *Trends Microbiol*. 2014;22:1–15.
18. Hernández Del Pino RE, Barbero AM, Español LÁ, et al. . *J Leukoc Biol*. 2021;109:195–210.
19. Lim SC, Knight DR, Riley T V. . *Clin Microbiol Infect*. 2020;26:857–863.
20. Donskey CJ. . *Clin Infect Dis*. 2010;50:1458–1461.
21. Dicks LMT. . *Microorganisms*;11 . Epub ahead of print 2023. DOI: 10.3390/microorganisms11092161.
22. Czepiel J, Dróżdż M, Pituch H, et al. . *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol*. 2019;38:1211–1221.

23. Huang CH, Tseng YH, Tsai WS, et al. . *Infect Dis Ther* . Epub ahead of print 2024. DOI: 10.1007/s40121-024-00922-5.

24. Song JH, Kim YS. . *Gut Liver*. 2019;13:16–24.

25. Nitzan O, Elias M, Chazan B, et al. . *World J Gastroenterol*. 2013;19:7577–7585.

26. Qu H-Q, Jiang Z-D. . *Diabetes Res Clin Pract*. 2014;105:285–294.

27. Dudzicz S, Wiecek A, Adamczak M. . *J Clin Med*. 2021;10:1–13.

28. Sartelli M, Malangoni MA, Abu-Zidan FM, et al. . *World J Emerg Surg*. 2015;10:1–23.

29. Khanna S, Pardi DS. . *Mayo Clin Proc*. 2012;87:1106–1117.

30. Curcio D, Cané A, Fernández FA, et al. . *Infect Dis Ther*. 2019;8:87–103.

31. Roldan GA, Cui AX, Pollock NR. . *J Clin Microbiol*;56 . Epub ahead of print March 2018. DOI: 10.1128/JCM.01747-17.

32. Acuña-Amador L, Quesada-Gómez C, Rodríguez C. . *Anaerobe*;74 . Epub ahead of print 2022. DOI: 10.1016/j.anaerobe.2022.102547.

33. Crobach MJT, Planche T, Eckert C, et al. . *Clin Microbiol Infect*. 2016;22:S63–S81.

34. Johnson S, Lavergne V, Skinner AM, et al. . *Clin Infect Dis*. 2021;73:e1029–e1044.

35. Viechtbauer W. . *J Stat Softw*. 2010;36:1–48.

36. Fernandez Canigia L, Nazar J, Arce M, et al. . *Rev Argent Microbiol*. 2001;33:101–107.

37. Legaria MC, Lumelsky G, Rosetti S. . *Anaerobe*. 2003;9:113–116.

38. Goorhuis A, Legaria MC, van den Berg RJ, et al. . *Clin Microbiol Infect*. 2009;15:1080–1086.

39. Lopardo G, Morfin-Otero R, Moran-Vazquez II, et al. . *Brazilian J Infect Dis*. 2015;19:8–14.

40. Bartlett JG, Gerding DN. . *Clinical Infectious Diseases*;46 . Epub ahead of print January 2008. DOI: 10.1086/521863.

41. Pan L, Mu M, Yang P, et al. . *Am J Gastroenterol*. 2020;115:766–773.

42. Granata G, Petrosillo N, Al Moghazi S, et al. . *Anaerobe*. 2022;74:102484.

43. Huttner BD, Catho G, Pano-Pardo JR, et al. . *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2020;26:808–810.

44. Chen N, Zhou M, Dong X, et al. . *Lancet (London, England)*. 2020;395:507–

513.

45. Adams-Sommer V, Fu Y, Grinspan LT, et al. . *Infect Control Hosp Epidemiol*. 2021;42:1165–1166.

46. Laszkowska M, Kim J, Faye AS, et al. . *Dig Dis Sci*. 2021;66:4398–4405.

47. Hawes AM, Desai A, Patel PK. . *Anaerobe*. 2021;70:102384.

48. Luo M, Liu Y, Wu P, et al. . 8 . Epub ahead of print 2017. DOI: 10.3389/fphys.2017.00822.

49. Khanna S, Kraft CS. . *Future Microbiol*. 2021;16:439–443.

50. Tariq R, Saha S, Furqan F, et al. . *Mayo Clin Proc*. 2020;95:1632–1648.

51. Louie TJ, Cannon K, Byrne B, et al. . *Clin Infect Dis an Off Publ Infect Dis Soc Am*. 2012;55 Suppl 2:S132-42.

52. Guh AY, Mu Y, Winston LG, et al. . *N Engl J Med*. 2020;382:1320–1330.

53. Gentry CA, Williams RJ 2nd, Campbell D. . *Diagn Microbiol Infect Dis*. 2021;100:115308.

54. McDermott LA, Thorpe CM, Goldstein E, et al. . *Open Forum Infect Dis*. 2022;9:ofac492.1299.

55. Dingle KE, Didelot X, Quan TP, et al. . *Lancet Infect Dis*. 2017;17:411–421.

56. Wilcox MH, Shetty N, Fawley WN, et al. . *Clin Infect Dis*. 2012;55:1056–1063.

57. Khanna S, Pardi DS, Aronson SL, et al. . *Am Coll Gastroenterol*;107.

58. European Centre for Disease Prevention and Control. . *Annu Epidemiol Rep Commun Dis Eur*. 2016;40:335–348.

59. Carlson TJ, Blasingame D, Gonzales-Luna AJ, et al. . *Anaerobe*. 2020;62:102142.

60. Kincaid SE. . *Consult Pharm J Am Soc Consult Pharm*. 2010;25:834–836.

61. Owens RC. . *Drugs*. 2007;67:487–502.

62. Bassaris HP, Lianou PE, Legakis NJ, et al. . *Med Microbiol Immunol*. 1984;173:49–55.

63. Nakamura S, Mikawa M, Nakashio S, et al. . *Microbiol Immunol*. 1981;25:345–351.

64. Bacon AE, Fekety R. . *Diagn Microbiol Infect Dis*. 1994;18:205–209.

65. Simor AE, Bradley SF, Strausbaugh LJ, et al. . *Infect Control Hosp Epidemiol*. 2002;23:696–703.

66. Guerrero DM, Nerandzic MM, Jury LA, et al. . *Am J Infect Control*.

2012;40:556–558.

67. Edwards AN, Karim ST, Pascual RA, et al. . *Front Microbiol*. 2016;7:1698.

68. Clark T, Wiselka M. . *Clin Med*. 2008;8:544–547.

69. Schroeder MS. . *Am Fam Physician*. 2005;71:921–928.

70. Hessen MT. . *Ann Intern Med*. 2010;153:ITC41-15; quiz ITC416.

71. Dubberke ER, Wertheimer AI. . *Infect Control Hosp Epidemiol*. 2009;30:57–66.

72. Wanahita A, Goldsmith EA, Marino BJ, et al. . *Am J Med*. 2003;115:543–546.

73. Wanahita A, Goldsmith EA, Musher DM. . *Clin Infect Dis an Off Publ Infect Dis Soc Am*. 2002;34:1585–1592.

74. Bulusu M, Narayan S, Shetler K, et al. . *Am J Gastroenterol*. 2000;95:3137–3141.

75. Vargas E, Apewokin S, Madan R. . *Anaerobe*. 2017;45:101–105.

76. Mihăilă RG, Cătană C, Olteanu AL, et al. . *Biomarkers*. 2019;24:389–393.

77. Buchrits S, Gafter-Gvili A, Bishara J, et al. . *J Clin Med*;10 . Epub ahead of print July 2021. DOI: 10.3390/jcm10132957.

78. Lee DY, Chung EL, Guend H, et al. . *Ann Surg*. 2014;259:148–156.

79. Byrn JC, Maun DC, Gingold DS, et al. . *Med Hist*. 2012;143:150–154.

80. Nseir W, Khamisy-Farah R, Amara A, et al. . *Isr Med Assoc J*. 2019;21:658–661.

81. Allegretti JR, Marcus J, Storm M, et al. . *Dig Dis Sci*. 2020;65:1761–1766.

82. Zhao L, Luo Y, Bian Q, et al. . *Infect Drug Resist*. 2020;13:171–181.

83. Pant C, Madonia PN, Jordan P, et al. . *J Investig Med*. 2009;57:40–42.

84. Yan D, Chen Y, Lv T, et al. . *J Med Microbiol*. 2017;66:1483–1488.

85. Phanchana M, Phetruen T, Harnvoravongchai P, et al. . *Sci Rep*. 2020;10:1–8.

86. Barbero AM, Hernández Del Pino RE, Fuentes F, et al. . 2024;1–14.

87. Rao K, Erb-Downward JR, Walk ST, et al. . *PLoS One*. 2014;9:e92578.

88. Abhyankar MM, Ma JZ, Scully KW, et al. . *Am Soc Microbiol*. 2020;11:1–10.

89. Abou Chakra CN, McGeer A, Labbe AC, et al. . *Clin Infect Dis*. 2015;61:1781–1788.

90. Sartelli M, Di Bella S, McFarland L V., et al. . *World J Emerg Surg*. 2019;14:1–29.

91. Bermejo Boixareu C, Tutor-Ureta P, Ramos Martínez A. . *Rev Esp Geriatr Gerontol*. 2020;55:225–235.

92. Lopes Cançado GG, Silveira Silva RO, Rupnik M, et al. . *Anaerobe*. 2018;54:65–71.

93. Lowe DO, Mamdani MM, Kopp A, et al. Proton Pump Inhibitors and Hospitalization for Clostridium Difficile-Associated Disease: A Population-Based Study.

94. Dai W, Yang T, Yan L, et al. . *BMC Infect Dis*;20 . Epub ahead of print April 2020. DOI: 10.1186/s12879-020-05014-6.

95. Li Y, Huang Y, Li Y, et al. . *Pakistan J Med Sci*. 2016;32:736–741.

96. Lv Z, Peng GL, Su JR. . *Brazilian J Med Biol Res*. 2014;47:1085–1090.

97. Tang C, Li Y, Liu C, et al. . *Am J Infect Control*. 2018;46:285–290.

98. Zhou FF, Wu S, Klena JD, et al. . *Eur J Clin Microbiol Infect Dis*. 2014;33:1773–1779.

99. Carvajal C, Pacheco C, Jaimes F. . *Biomedica*. 2017;37:53–61.

100. Salazar CL, Reyes C, Atehortua S, et al. . *PLoS One*;12 . Epub ahead of print September 2017. DOI: 10.1371/journal.pone.0184689.

101. Soes LM, Holt HM, Böttiger B, et al. . *Epidemiol Infect*. 2014;142:1437–1448.

102. Le Monnier A, Candela T, Mizrahi A, et al. . *J Hosp Infect*. 2022;129:65–74.

103. Kurti Z, Lovasz BD, Mandel MD, et al. . *World J Gastroenterol*. 2015;21:6728–6735.

104. Vesteinsdottir I, Gudlaugsdottir S, Einarsdottir R, et al. . *Eur J Clin Microbiol Infect Dis*. 2012;31:2601–2610.

105. Ingle M, Deshmukh A, Desai D, et al. . *Indian J Gastroenterol*. 2011;30:89–93.

106. Ingle M, Deshmukh A, Desai D, et al. . *Indian J Gastroenterol*. 2013;32:179–183.

107. Mori N, Aoki Y. . *J Infect Chemother*. 2015;21:864–867.

108. Morfin-Otero R, Garza-Gonzalez E, Aguirre-Diaz SA, et al. . *Brazilian J Infect Dis*. 2016;20:8–13.

109. Czepiel J, Biesiada G, Brzozowski T, et al. . *J Physiol Pharmacol an Off J Polish Physiol Soc*. 2014;65:695–703.

110. Legenza L, Barnett S, Rose W, et al. . *BMJ Glob Heal*;3 . Epub ahead of print July 2018. DOI: 10.1136/bmjgh-2018-000889.

111. Rajabally N, Pentecost M, Pretorius G, et al. . *South African Med J*.

2013;103:168–172.

112. Han SH, Kim H, Lee K, et al. . *J Med Microbiol*. 2014;63:1542–1551.

113. Lee YC, Wang JT, Chen AC, et al. . *J Microbiol Immunol Infect*. 2012;45:287–295.

114. Lin C-Y, Cheng H-T, Kuo C-J, et al. . *Microbiol Spectr*;10 . Epub ahead of print August 2022. DOI: 10.1128/spectrum.00486-22.

115. Thipmontree W, Kiratisin P, Manatsathit S, et al. Epidemiology of Suspected Clostridium difficile-Associated Hospital-Acquired Diarrhea in Hospitalized Patients at Siriraj Hospital. 2011.

116. Ergen EK, Akalin H, Yilmaz E, et al. . *Med Mal Infect*. 2009;39:382–387.

117. Dial S, Delaney JAC, Barkun AN, et al. . *JAMA*. 2005;294:2989–2995.

118. Dial S, Kezouh A, Dascal A, et al. . *C Can Med Assoc J*. 2008;179:767–772.

119. Marwick CA, Yu N, Lockhart MC, et al. . *J Antimicrob Chemother*. 2013;68:2927–2933.

120. Suissa D, Delaney JAC, Dial S, et al. . *Br J Clin Pharmacol*. 2012;74:370–375.

121. Wilcox MH, Mooney L, Bendall R, et al. . *J Antimicrob Chemother*. 2008;62:388–396.

122. Baxter R, Ray GT, Fireman BH. . *Infect Control Hosp Epidemiol*. 2008;29:44–50.

123. Haddad FG, Zaidan J, Polavarapu A, et al. . *Z Gastroenterol*. 2019;57:1183–1195.

124. Kuntz JL, Chrischilles EA, Pendergast JF, et al. . *BMC Infect Dis*;11 . Epub ahead of print July 2011. DOI: 10.1186/1471-2334-11-194.

125. Kutty PK, Woods CW, Sena AC, et al. . *Emerg Infect Dis*. 2010;16:197–204.

126. Kwon SS, Gim JL, Kim MS, et al. . *Anaerobe*. 2017;48:42–46.

127. Naggie S, Miller BA, Zuzak KB, et al. . *Am J Med*;124 . Epub ahead of print March 2011. DOI: 10.1016/j.amjmed.2010.10.013.

128. Tabak YP, Johannes RS, Sun X, et al. . *Infect Control Hosp Epidemiol*. 2015;36:695–701.

129. Tartof SY, Rieg GK, Wei R, et al. . *Infect Control Hosp Epidemiol*. 2015;36:1409–1416.

130. Hensgens MPM, Goorhuis A, Dekkers OM, et al. . *J Antimicrob Chemother*. 2012;67:742–748.

131. Nardino RJ, Vender RJ, Herbert PN. . *Am J Gastroenterol*. 2000;95:3118–

3122.

132. Herzig SJ, Howell MD, Ngo LH, et al. . *JAMA*. 2009;301:2120–2128.

133. Pham CQD, Regal RE, Bostwick TR, et al. . *Ann Pharmacother*. 2006;40:1261–1266.

134. Freedberg DE, Lebwohl B, Abrams JA. . *Clin Lab Med*. 2014;34:771–785.

135. Singh A, Cresci GA, Kirby DF. . *Nutr Clin Pract Off Publ Am Soc Parenter Enter Nutr*. 2018;33:614–624.

136. van Prehn J, Reigadas E, Vogelzang EH, et al. . *Clin Microbiol Infect*. 2021;27:S1–S21.

137. Furuya-Kanamori L, Stone JC, Clark J, et al. . *Infect Control Hosp Epidemiol*. 2015;36:132–141.


a)
21.29% Positive
76.70% Negative
02.01% Discordant
b)
81.13% Toxigenic
18.87% Non toxigenic
c)
100
75
50
25
0
% Patients
2019 2020 2021 2022 2023
YEARS
DISCORDANT
NEGATIVE
POSITIVE
d)
100.00% Moderate
e)
33.33% Community-acquired
43.59% Hospital-acquired
23.08% Community-acquired associated to healthcare environments


a)
Age (years)
CDI-
CDI+
b)
ROC curve: ROC of Age (years)
c)
% Patients
ns
Female
Male
d)
% Patients
Without prior ATB consumption
With prior ATB consumption
e)
% Patients
Without prior hospitalization
With prior hospitalization
f)
% Patients
Without prior CDI
With prior CDI
g)
56.52% Penicillin
13.04% Glycopeptides
08.70% Cephalosporins
08.70% Fluoroquinolones
08.70% Sulfonamides
04.35% Lincosamides
h)
% Patients
Without prior PPI consumption
With prior PPI consumption
i)
% Patients
Without prior comorbidities
With prior comorbidities
j)
% Patients
PNEUMONIA
DEPRESSION
HEART DISEASE
CVA (Cerebrovascular Accident)
CONVULSIONS
CKD (Chronic Kidney Disease)
CHF (Congestive Heart Failure)
HTN (Hypertension)
HYPOTHYROIDISM
COPD (Chronic Obstructive Pulmonary Disease)
GELAC DISEASE
TB (Tuberculosis)
MI (Myocardial Infarction)
HYPERTHYROIDISM
CROHN'S DISEASE
PARKINSON'S DISEASE


a)
Leukocytes (cel./mm3)
3×10⁴
2×10⁴
1×10⁴
0
*
CDI-
CDI+
b)
Lymphocytes (cel./mm3)
4×10³
3×10³
2×10³
1×10³
0
ns (p = 0.0505)
CDI-
CDI+
c)
Monocytes (cel./mm3)
2×10³
1.5×10³
1×10³
5×10²
0
ns (p = 0.0625)
CDI-
CDI+
d)
Neutrophils (cel./mm3)
2.5×10⁴
2×10⁴
1.5×10⁴
1×10⁴
5×10³
0
ns (p = 0.0714)
CDI-
CDI+
e)
Limphocytes+Monocytes (cel./mm3)
5×10³
4×10³
3×10³
2×10³
1×10³
0
*
CDI-
CDI+
f)
Limphocytes+Neutrophils (cel./mm3)
2.5×10⁴
2×10⁴
1.5×10⁴
1×10⁴
5×10³
0
*
CDI-
CDI+
g)
Neutrophils+Monocytes (cel./mm3)
5×10³
4×10³
3×10³
2×10³
1×10³
0
*
CDI-
CDI+
h)
Basophils (cel./mm3)
4×10¹
3×10¹
2×10¹
1×10¹
0
**
CDI-
CDI+
i)
Eosinophils (cel./mm3)
4×10²
3×10²
2×10²
1×10²
0
ns
CDI-
CDI+
j)
Platelets (cel./mm3)
8×10⁵
6×10⁵
4×10⁵
2×10⁵
0
*
CDI-
CDI+
k)
Creatinine (mg/dl)
3
2
1
0
ns
CDI-
CDI+
l)
Albumin (g/dl)
4
3
2
1
0
ns
CDI-
CDI+
m)
Urea (mg/dl)
150
100
50
0
*
CDI-
CDI+
n)
Ratio BUN / Creatinine
100
80
60
40
20
0
*
CDI-
CDI+

a)



Identified studies in PubMed (3,701 articles), Google Scholar (229 articles) and SciSpace.
63 studies excluded
102 studies assessed for Eligibility
40 studies included in Meta-analysis
Package "Metafor"
Identification
Eligibility
Included
Analysis
Search terms: "CDI", "C. difficile", "Clinical records", "Epidemiology", "Cases and controls study"
Inclusion criteria
Over 18 years old
Cases (patients with diarrhea and a positive CDI diagnosis by EIA, PCR and/or toxigenic culture)
Controls (patients with diarrhea and a negative CDI diagnosis)
Variables of interest (Age, Biological sex, Use of antibiotics in the previous 3 months, Use of proton pump inhibitors, Leukocyte count, Platelet count, Presence of comorbidities (Diabetes mellitus, Heart disease, Kidney disease, HIV))

b)

5
1
1
1
1
1
1
8
5
1
2
1
1
1
1
2
2
1
2
2


a)
Age
Carvajal, C. et al, 2017
Czepiel, J. et al, 2014
Dial, S. et al, 2009
Dial, S. et al, 2009
Ergen, E. K. et al, 2009
Haddad, F. G. et al, 2019
Han, S. H. et al, 2014
Ingle, M. et al, 2011
Ingle, M. et al, 2011
Lee, Y. C. et al, 2012
Li, Y. et al, 2016
Lin, C.-Y. et al, 2022
Lopes Cançado, G. G. et al, 2018
Lowe, D. O. et al, 2009
Lv, Z. et al, 2014
Marwick, C. A. et al, 2015
OUR STUDY
Tang, C. et al, 2019
Tartuf, S. Y. et al, 2016
REML
Studies
SMD
b)
Sex
OR
c)
Prior ATB consumption
OR
d)
Prior PPI consumption
OR
e)
Prior hospitalization
OR
f)
Prior CDI
Haddad, F. G. et al, 2019
Kurti, Z. et al, 2015
OUR STUDY
Suissa, D. et al, 2012
Wilcox, M. H. et al, 2008
REML
Studies
OR
I² = 90,39%, p = 0.6198
g)
Heart Disease
OR
h)
Chronic Kidney Disease
OR
i)
Diabetes mellitus
OR
j)
HIV
Ingle, M. et al, 2013
Legenza, L. et al, 2013
OUR STUDY
Rajabally, N. et al, 2013
Thipsontree, W. et al, 2011
REML
Studies
OR
I² = 39.12%, p = 0.9939
k)
WBC
Carvajal, C. et al, 2017
Czepiel, J. et al, 2014
Han, S. H. et al, 2014
Kurti, Z. et al, 2015
Lee, Y. C. et al, 2012
Li, Y. et al, 2016
Lin, C.-Y. et al, 2022
Lv, Z. et al, 2014
OUR STUDY
REML
Studies
SMD
I² = 94,96%, p = 0.0191
l)
Platelets count
Czepiel, J. et al, 2014
Lin, C. Y. et al, 2022
OUR STUDY
REML
Studies
SMD
I² = 81,78%, p = 0.0596


STUDY COHORT
Diagnostic algorithm
Clinical records
20%
of patients had C. difficile as the causal agent of their diarrheas
>30%
of CDI infections occurred in the community setting
80%
of the patients were infected with toxigenic strains
100%
of infected patients had a moderate diarrhea classification
RISK FACTORS
Advanced age
Prior antibiotic use
Prior hospitalization
Prior CDI
Leukocytosis
Thrombocytosis
Basophilopenia
Elevated urea
Meta-analysis
GLOBAL RISK FACTORS
Advanced age
Female
Prior antibiotic use
Prior hospitalization
Leukocytosis
Chronic kidney disease
Heart diseases

SANITARY REGION III



JUNIN REGION HEADQUARTERS

H Hospital Interzonal General de Agudos Abraham Piñeyro
C.P.A.: Provincial Center for Addiction Care


Step 1:
Direct PCR or
EIA GDH and
toxins
Both positive
No other tests are required:
CDI or toxigenic C. difficile
carriage*
1 of the two negative
Step 2:
Toxigenic culture
Positive result
CDI or toxigenic
C. difficile carriage*
Negative result
CDI may not be
present*
Both negative
No additional tests required
*clinical evaluation is required in all cases


a)
ns
100
50
0
% Patients
CDI-
CDI+
ICU
Common floor
b)
ns
100
50
0
% Patients
CDI-
CDI+
Without ICU
With ICU
c)
ns
100
50
0
% Patients
CDI-
CDI+
Moderate
Severe
d)
ns
100
50
0
% Patients
CDI-
CDI+
Without shock
With shock
e)
ns
100
50
0
% Patients
CDI-
CDI+
Without death
With death